The U.S. drugmaker hopes the drug, upadacitinib, can help replace lost revenue from its top-selling RA treatment Humira.
24 Oct 2018 5:45 AM GMT
Allergan shareholders will receive 0.8660 AbbVie shares and USD 120.30 in cash for each share held.
25 Jun 2019 11:13 AM GMT